Your browser is no longer supported. Please, upgrade your browser.
ARVN Arvinas, Inc. weekly Stock Chart
Arvinas, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own3.10% Shs Outstand38.55M Perf Week1.19%
Market Cap2.78B Forward P/E- EPS next Y-2.75 Insider Trans-2.22% Shs Float23.48M Perf Month0.92%
Income-77.60M PEG- EPS next Q-0.59 Inst Own83.10% Short Float14.03% Perf Quarter-15.41%
Sales45.20M P/S61.58 EPS this Y72.20% Inst Trans3.26% Short Ratio5.08 Perf Half Y-18.24%
Book/sh5.49 P/B6.17 EPS next Y-12.70% ROA-32.20% Target Price- Perf Year35.96%
Cash/sh3.20 P/C10.59 EPS next 5Y- ROE-45.10% 52W Range15.19 - 61.57 Perf YTD-17.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.97% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low123.11% ATR2.46
Employees133 Current Ratio8.10 Sales Q/Q55.00% Oper. Margin- RSI (14)45.40 Volatility5.87% 6.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.60% Profit Margin- Rel Volume0.44 Prev Close34.15
ShortableYes LT Debt/Eq0.01 EarningsMar 24 BMO Payout- Avg Volume648.87K Price33.88
Recom1.80 SMA204.24% SMA50-18.40% SMA200-12.24% Volume287,733 Change-0.79%
Jun-01-20Upgrade Citigroup Neutral → Buy $45
May-12-20Initiated Oppenheimer Perform
Dec-19-19Initiated H.C. Wainwright Buy $50
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Jun-29-20 04:30PM  
Jun-17-20 07:00AM  
Jun-15-20 09:48AM  
Jun-11-20 07:00AM  
Jun-05-20 12:00PM  
May-29-20 10:28AM  
May-20-20 04:30PM  
May-14-20 12:33PM  
May-13-20 05:49PM  
May-12-20 08:54AM  
May-05-20 12:00PM  
May-01-20 06:33AM  
Apr-28-20 09:37AM  
Apr-18-20 10:02AM  
Apr-13-20 04:54PM  
Mar-31-20 07:00AM  
Mar-20-20 11:30AM  
Mar-19-20 08:56AM  
Mar-18-20 06:52AM  
Mar-16-20 08:15AM  
Feb-17-20 12:00PM  
Jan-31-20 09:31AM  
Jan-29-20 06:51AM  
Jan-17-20 05:37AM  
Dec-19-19 06:27PM  
Nov-27-19 07:30AM  
Nov-26-19 08:06AM  
Nov-25-19 11:40AM  
Nov-21-19 07:30AM  
Nov-17-19 12:44PM  
Nov-06-19 09:40PM  
Nov-05-19 09:00AM  
Nov-04-19 05:00PM  
Oct-31-19 11:50AM  
Oct-30-19 09:36AM  
Oct-23-19 07:54AM  
Oct-20-19 08:08AM  
Oct-19-19 09:02AM  
Oct-17-19 07:00AM  
Oct-02-19 07:00AM  
Oct-01-19 02:54PM  
Sep-25-19 02:44PM  
Aug-27-19 07:00AM  
Aug-16-19 12:46PM  
Aug-07-19 07:00AM  
Aug-05-19 07:00AM  
Jul-31-19 01:48PM  
Jul-29-19 07:00AM  
Jul-25-19 07:00AM  
Jul-18-19 07:00AM  
Jun-27-19 06:54AM  
Jun-26-19 06:28PM  
Jun-25-19 07:00AM  
Jun-20-19 08:30AM  
Jun-06-19 07:00AM  
Jun-04-19 07:00AM  
May-29-19 07:00AM  
May-11-19 01:30PM  
May-08-19 07:00AM  
Apr-02-19 07:00AM  
Mar-26-19 07:00AM  
Mar-25-19 07:00AM  
Mar-16-19 09:16AM  
Feb-07-19 04:30PM  
Feb-01-19 12:08PM  
Jan-04-19 05:00PM  
Dec-07-18 07:00PM  
Nov-20-18 06:00AM  
Oct-23-18 07:30AM  
Oct-03-18 08:15PM  
Sep-27-18 10:42AM  
Sep-26-18 08:06PM  
Sep-22-18 04:15PM  
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHANNON TIMOTHY MDirectorJun 17Buy30.262,00060,52079,546Jun 19 05:00 PM
SHANNON TIMOTHY MDirectorJun 02Buy32.303,00096,90077,546Jun 04 09:00 PM
Ratcliffe LiamDirectorMay 26Option Exercise22.066,500143,3906,500May 27 06:34 PM
SHANNON TIMOTHY MDirectorMay 26Option Exercise22.0612,923285,08174,546May 26 07:05 PM
Cassidy Sean AChief Financial OfficerMay 13Option Exercise16.001,35621,696151,778May 14 09:30 PM
Cassidy Sean AChief Financial OfficerMay 12Sale60.0010,000600,000150,422May 14 09:25 PM
Morrison BriggsDirectorMar 24Buy38.182,50095,45029,520Mar 25 04:45 PM
Cassidy Sean AChief Financial OfficerMar 23Option Exercise16.008,030128,480160,422Mar 24 07:30 AM
Houston John GPresident and CEOMar 23Option Exercise16.006,250100,000816,200Mar 24 07:48 PM
SHANNON TIMOTHY MDirectorMar 20Buy40.002,500100,00061,623Mar 23 07:01 PM
Houston John GPresident and CEOMar 19Sale37.615,405203,282809,950Mar 23 09:55 PM
Taylor IanChief Scientific OfficerMar 19Sale37.6182631,06670,398Mar 23 09:45 PM
Cassidy Sean AChief Financial OfficerMar 19Sale37.611,51456,942152,392Mar 23 09:35 PM
Margus Bradley AlbertDirectorMar 18Sale37.4640,0001,498,40059,463Mar 20 05:30 PM
Cassidy Sean AChief Financial OfficerFeb 07Sale51.0210,000510,157149,115Feb 11 06:00 PM
Taylor IanChief Scientific OfficerJan 28Option Exercise16.0013,042208,67268,538Jan 30 06:00 PM
Houston John GPresident and CEODec 17Option Exercise16.0012,500200,000797,844Dec 19 04:59 PM
Cassidy Sean AChief Financial OfficerNov 19Sale32.0010,000320,000159,115Nov 21 05:45 PM
Taylor IanChief Scientific OfficerNov 13Sale28.0010,000280,00055,496Nov 15 05:13 PM
Ratcliffe LiamDirectorNov 12Buy22.00680,00014,960,000680,000Nov 14 04:23 PM